Two domains of vimentin are expressed on the surface of lymph node, bone and brain metastatic prostate cancer lines along with the putative stem cell marker proteins CD44 and CD133

Cancers

Volumn 3, Issue 3, 2011, Pages 2870-2885

  Steinmetz, Nicole F ^a   Maurer, Jochen ^b   Sheng, Huiming ^c   Bensussan, Armand ^d,e   Maricic, Igor ^c   Kumar, Vipin ^c   Braciak, Todd A ^c  

^a Case Western Reserve University   (United States)

^b BURNHAM INSTITUTE   (United States)

^c TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cowpea mosaic virus; Metastases; Prostate cancer; Stem cell; Vimentin

Indexed keywords

CD133 ANTIGEN; COWPEA MOSAIC VIRUS NANOPARTICLE; HERMES ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SC5; MONOCLONAL ANTIBODY V9; NANOPARTICLE; UNCLASSIFIED DRUG; VIMENTIN;

ANTIGEN EXPRESSION; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL SPECIFICITY; CELL SURFACE; COIL 1 ROD DOMAIN; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MALE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION;

EID: 80053213759     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3032870     Document Type: Article

References (46)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
2. Sgrignoli, A.R.; Walsh, P.C.; Steinberg, G.D.; Steiner, M.S.; Epstein, J.I. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J. Urol. 1994, 152, 1077-1081.
3. Yagoda, A.; Petrylak, D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993, 71, 1098-1109.
4. Wu, M.; Bai, X.; Xu, G.; Wei, J.; Zhu, T.; Zhang, Y.; Li, Q.; Liu, P.; Song, A.; Zhao, L.; Gang, C.; Han, Z.; Wang, S.; Zhou, J.; Lu, Y.; Ma, D. Proteome analysis of human androgen-independent prostate cancer cell lines: Variable metastatic potentials correlated with vimentin expression. Proteomics 2007, 7, 1973-1983.
5. Jordan, C.T.; Guzman, M.L.; Noble, M. Cancer stem cells. N. Engl. J. Med. 2006, 355, 1253-1261.
6. Yang, J.; Weinberg, R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14, 818-829.
7. Luo, Y.; He, D.L.; Jiang, Y.G.; Li, M.C.; Ning, L.; Shen, S.L. Over-expression of HIF-1alpha induces EMT of human prostate cancer cells. Zhonghua Nan Ke Xue 2008, 14, 800-804.
8. Huet, D.; Bagot, M.; Loyaux, D.; Capdevielle, J.; Conraux, L.; Ferrara, P.; Bensussan, A.; Marie-Cardine, A. SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells. J. Immunol. 2006, 176, 652-659.
9. Hagiwara, H.; Sato, G.H. Human X human hybridoma producing monoclonal antibody against autologous cervical carcinoma. Mol. Biol. Med. 1983, 1, 245-252.
10. Kokunai, T.; Tamaki, N.; Matsumoto, S. Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody. J. Neurosurg. 1990, 73, 901-908.
11. Aotsuka, Y.; Hagiwara, H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 1988, 24, 829-838.
12. Glassy, M.C.; Hagiwara, H. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. Hum. Antibodies 2009, 18, 127-137.
13. Patrawala, L.; Calhoun-Davis, T.; Schneider-Broussard, R.; Tang, D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007, 67, 6796-6805.
14. Collins, A.T.; Habib, F.K.; Maitland, N.J.; Neal, D.E. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J. Cell Sci. 2001, 114, 3865-3872.
15. Richardson, G.D.; Robson, C.N.; Lang, S.H.; Neal, D.E.; Maitland, N.J.; Collins, A.T. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 2004, 117, 3539-3545.
16. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65, 10946-10951.
17. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Li, H.; Bhatia, B.; Tang, S.; Reilly, J.G.; Chandra, D.; Zhou, J.; Claypool, K.; Coghlan, L.; Tang, D.G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25, 1696-1708.
18. Zoller, M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 2011, 11, 254-267.
19. Marhaba, R.; Klingbell, P.; Nuebel, T.; Nazarenko, I.; Buechler, M.W.; Zoller, M. CD44 and EpCAM: cancer-initiating cell markers. Curr. Mol. Med. 2008, 8, 784-804.
20. Wei, C.; Guomin, W.; Yujun, L.; Ruizhe, Q. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol. Ther. 2007, 6, 763-768.
21. Pokorski, J.K.; Steinmetz, N.F. The art of engineering viral nanoparticles. Mol. Pharm. 2011, 8, 29-43.
22. Koudelka, K.J.; Destito, G.; Plummer, E.M.; Trauger, S.A.; Siuzdak, G.; Manchester, M. Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin. PLoS Pathog. 2009, 5, e1000417.
23. Steinmetz, N.F.; Cho, C.-F.; Ablack, A.; Lewis, J.D.; Manchester, M. Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomedicine (Lond.) 2011, 6, 351-364.
24. Nikolova, M.; Tawab, A.; Marie-Cardine, A.; Bagot, M.; Boumsell, L.; Bensussan, A. Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells. J. Invest. Dermatol. 2001, 116, 731-738.
25. Wellink, J. Comovirus isolation and RNA extraction. Methods Mol. Biol. 1998, 81, 205-209.
26. Li, H.; Chen, X.; Calhoun-Davis, T.; Claypool, K.; Tang, D.G. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res. 2008, 68, 1820-1825.
27. Aruffo, A.; Stamenkovic, I.; Melnick, M.; Underhill, C.B.; Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61, 1303-1313.
28. Okamoto, I.; Kawano, Y.; Murakami, D.; Sasayama, T.; Araki, N.; Miki, T.; Wong, A.J.; Saya, H. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J. Cell Biol. 2001, 155, 755-762.
29. Kim, D.H.; Wirtz, D. Recapitulating cancer cell invasion in vitro. Proc. Natl. Acad. Sci. USA 2011, 108, 6693-6694.
30. Liu, L.; Sun, B.; Pedersen, J.N.; Aw Yong, K.M.; Getzenberg, R.H.; Stone, H.A.; Austin, R.H. From the Cover: Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape. Proc. Natl. Acad. Sci. USA 2011, 108, 6853-6856.
31. Kajita, M.; Itoh, Y.; Chiba, T.; Mori, H.; Okada, A.; Kinoh, H.; Seiki, M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell Biol. 2001, 153, 893-904.
32. Shao, R.; Guo, X. Human microvascular endothelial cells immortalized with human telomerase catalytic protein: A model for the study of in vitro angiogenesis. Biochem. Biophys. Res. Commun. 2004, 321, 788-794.
33. van Beijnum, J.R.; Dings, R.P.; van der Linden, E.; Zwaans, B.M.; Ramaekers, F.C.; Mayo, K.H.; Griffioen, A.W. Gene expression of tumor angiogenesis dissected: Specific targeting of colon cancer angiogenic vasculature. Blood 2006, 108, 2339-2348.
34. Lewis, J.D.; Destito, G.; Zijlstra, A.; Gonzalez, M.J.; Quigley, J.P.; Manchester, M.; Stuhlmann, H. Viral nanoparticles as tools for intravital vascular imaging. Nat. Med. 2006, 12, 354-360.
35. Steinmetz, N.F.; Manchester, M. PEGylated viral nanoparticles for biomedicine: The impact of PEG chain length on VNP cell interactions in vitro and ex vivo. Biomacromolecules 2009, 10, 784-792.
36. Tang, D.G.; Patrawala, L.; Calhoun, T.; Bhatia, B.; Choy, G.; Schneider-Broussard, R.; Jeter, C. Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Mol. Carcinog. 2007, 46, 1-14.
37. Mori, H.; Tomari, T.; Koshikawa, N.; Kajita, M.; Itoh, Y.; Sato, H.; Tojo, H.; Yana, I.; Seiki, M. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 2002, 21, 3949-3959.
38. Miraglia, S.; Godfrey, W.; Yin, A.H.; Atkins, K.; Warnke, R.; Holden, J.T.; Bray, R.A.; Waller, E.K.; Buck, D.W. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90, 5013-5021.
39. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828.
40. Suetsugu, A.; Nagaki, M.; Aoki, H.; Motohashi, T.; Kunisada, T.; Moriwaki, H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006, 351, 820-824.
41. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1, 313-323.
42. Eramo, A.; Lotti, F.; Sette, G.; Pilozzi, E.; Biffoni, M.; Di Virgilio, A.; Conticello, C.; Ruco, L.; Peschle, C.; De Maria, R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15, 504-514.
43. O'Brien, C.A.; Pollett, A.; Gallinger, S.; Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445, 106-110.
44. Shmelkov, S.V.; Butler, J.M.; Hooper, A.T.; Hormigo, A.; Kushner, J.; Milde, T.; St Clair, R.; Baljevic, M.; White, I.; Jin, D.K.; Chadburn, A.; Murphy, A.J.; Valenzuela, D.M.; Gale, N.W.; Thurston, G.; Yancopoulos, G.D.; D'Angelica, M.; Kemeny, N.; Lyden, D.; Rafii, S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J. Clin. Invest. 2008, 118, 2111-2120.
45. Tomas, D.; Kruslin, B. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate 2004, 61, 324-331.
46. Kugler, M.; Stein, C.; Kellner, C.; Mentz, K.; Saul, D.; Schwenkert, M.; Schubert, I.; Singer, H.; Oduncu, F.; Stockmeyer, B.; Mackensen, A.; Fey, G.H. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br. J. Haematol. 2010, 150, 574-586.